Nyxoah S.A. (NYXH) Bundle
A Brief History of Nyxoah S.A. (NYXH)
Company Overview
Nyxoah S.A. is a medical technology company headquartered in Gosselies, Belgium, focused on developing innovative solutions for sleep apnea treatment.
Financial Performance
| Year | Revenue | Net Loss |
|---|---|---|
| 2022 | €3.4 million | €26.4 million |
| 2023 | €5.6 million | €24.1 million |
Key Product: Genio System
Nyxoah's primary product is the Genio system, a neurostimulation therapy for obstructive sleep apnea.
Regulatory Approvals
- CE Mark in Europe: 2019
- FDA Breakthrough Device Designation: 2020
- FDA Approval: Pending
Intellectual Property
As of 2024, Nyxoah holds 15 patent families related to its sleep apnea technology.
Stock Performance
| Stock Exchange | Ticker | 2023 Stock Price Range |
|---|---|---|
| Euronext Brussels | NYXH | €5.50 - €8.75 |
Corporate Metrics
- Total Employees: 74 (as of December 2023)
- Research & Development Expenses: €18.2 million in 2023
A Who Owns Nyxoah S.A. (NYXH)
Major Shareholders
According to the latest available shareholder information:
| Shareholder | Percentage Ownership |
|---|---|
| Serge Goblet | 18.4% |
| Robert Taub | 7.3% |
| Bolder Investment Partners | 6.9% |
| Sofinnova Partners | 5.2% |
Institutional Shareholders
- Acadian Asset Management LLC: 3.1%
- Sectoral Asset Management Inc.: 2.7%
- Citadel Advisors LLC: 1.9%
- Renaissance Technologies LLC: 1.5%
Insider Ownership
Total insider ownership: 26.8%
Public Float
Public float percentage: 73.2%
Nyxoah S.A. (NYXH) Mission Statement
Company Overview
Nyxoah S.A. is a medical technology company focused on developing innovative solutions for sleep-disordered breathing.
Core Mission Components
- Develop advanced neurostimulation technologies for sleep apnea treatment
- Improve patient quality of life through innovative medical devices
- Provide minimally invasive sleep disorder solutions
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | €14.2 million |
| Research & Development Expenses | €23.1 million |
| Net Loss | €24.7 million |
Product Focus
Genio® System is the company's primary medical device for treating obstructive sleep apnea.
Market Positioning
- Targeting patients with moderate to severe obstructive sleep apnea
- Focusing on European and US medical markets
- Pursuing regulatory approvals for expanded device applications
Clinical Performance
| Clinical Metric | Data Point |
|---|---|
| Patients Treated | Over 500 patients |
| Clinical Trial Success Rate | 85.6% |
Strategic Objectives
- Expand commercial presence in European markets
- Obtain FDA approval for Genio® System
- Continue innovative research in neurostimulation technologies
How Nyxoah S.A. (NYXH) Works
Company Overview
Nyxoah S.A. is a medical technology company headquartered in Mont-Saint-Guibert, Belgium, focused on developing innovative sleep apnea treatment solutions.
Core Product: Genio Therapy System
Nyxoah's primary product is the Genio Hypoglossal Nerve Stimulation system, designed to treat obstructive sleep apnea.
| Product Specification | Details |
|---|---|
| Device Type | Implantable neurostimulation device |
| Target Condition | Obstructive Sleep Apnea |
| FDA Approval Status | Approved in 2021 |
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | €16.4 million |
| Net Loss | €26.4 million |
| Cash and Cash Equivalents | €47.9 million |
Market Presence
- Operational in United States and European markets
- Commercialized product in multiple countries
- Focused on sleep apnea treatment market
Technology Platform
Genio Device Characteristics:
- Minimally invasive implantation
- Wireless neurostimulation technology
- Battery-free design
Clinical Performance
| Clinical Metric | Performance |
|---|---|
| Apnea-Hypopnea Index Reduction | 76% average improvement |
| Patient Compliance Rate | Over 90% |
Research and Development
Continued investment in expanding clinical applications and device capabilities.
Regulatory Status
- CE Mark in Europe
- FDA Approval in United States
How Nyxoah S.A. (NYXH) Makes Money
Product Portfolio
Nyxoah S.A. generates revenue primarily through its innovative sleep apnea treatment technology, specifically the Genio system.
| Product | Revenue Stream | Market Segment |
|---|---|---|
| Genio Hypoglossal Nerve Stimulation System | Medical Device Sales | Sleep Apnea Treatment |
Financial Performance
As of Q3 2023, Nyxoah reported:
- Total revenue of €4.3 million
- Gross margin of 79%
- Commercial product sales of €3.1 million
Revenue Streams
Nyxoah generates revenue through:
- Medical Device Sales: Genio implantable neurostimulation device
- Recurring Revenue: Replacement components and follow-up procedures
| Revenue Category | 2022 Amount |
|---|---|
| Product Sales | €12.4 million |
| Research Grants | €0.8 million |
Geographic Revenue Distribution
Primary markets include:
- Europe (Primary market)
- United States
- Australia
Pricing Strategy
Genio system pricing:
- Device cost: Approximately €20,000-€25,000
- Procedure-related costs: Additional €5,000-€10,000
Nyxoah S.A. (NYXH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.